Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


The fourth HIV epidemic.

Laborde-Balen G, Taverne B, Ndour CT, Kouanfack C, Peeters M, Ndoye I, Delaporte E.

Lancet Infect Dis. 2018 Apr;18(4):379-380. doi: 10.1016/S1473-3099(18)30167-1. Epub 2018 Mar 21. No abstract available.


Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality.

Boussari O, Subtil F, Genolini C, Bastard M, Iwaz J, Fonton N, Etard JF, Ecochard R; ANRS 1215 study group.

BMC Med Res Methodol. 2015 Feb 5;15:10. doi: 10.1186/1471-2288-15-10.


Universal health coverage and HIV in resource-constrained countries: a critical juncture for research and action.

Taverne B, Desclaux A, Delaporte E, Ndoye I, Coll Seck AM, Barré-Sinoussi F.

AIDS. 2013 Sep 10;27(14):2173-5. doi: 10.1097/QAD.0b013e3283611a0e. Review. No abstract available.


Nonlinear multiple imputation for continuous covariate within semiparametric Cox model: application to HIV data in Senegal.

Mbougua JB, Laurent C, Ndoye I, Delaporte E, Gwet H, Molinari N.

Stat Med. 2013 Nov 20;32(26):4651-65. doi: 10.1002/sim.5854. Epub 2013 May 28.


Antiretroviral drugs in Africa: a public health versus a market approach.

Taverne B, Desclaux A, Koita Fall MB, Delaporte E, Ndoye I.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e74-6. doi: 10.1097/QAI.0b013e31828ed94d. No abstract available.


Development of a checklist of quality indicators for clinical trials in resource-limited countries: the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience.

Hanna M, Minga A, Fao P, Borand L, Diouf A, Mben JM, Gad RR, Anglaret X, Bazin B, Chene G; [Quali-PED] ANRS 12175 Study Group.

Clin Trials. 2013 Apr;10(2):300-18. doi: 10.1177/1740774512470765. Epub 2013 Jan 23.


Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821.


Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.

De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group.

Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222.


AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.

Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group.

Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4.


Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.

Laurent C, Tchatchueng Mbougua JB, Ngom Guèye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E; ANRS 1215/1290 Study Group.

Trop Med Int Health. 2011 Feb;16(2):217-22. doi: 10.1111/j.1365-3156.2010.02690.x. Epub 2010 Nov 19.


Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.

De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Guèye NF, Guèye PM, Sow PS, Mboup S, Ndoye I, Ecochard R, Eric D; ANRS 1215/90 Study Group.

Am J Trop Med Hyg. 2009 Jun;80(6):1047-53.


Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.


Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

De Beaudrap P, Etard JF, Ecochard R, Diouf A, Dieng AB, Cilote V, Ndiaye I, Guèye NF, Guèye PM, Sow PS, Mboup S, Ndoye I, Delaporte E.

Eur J Epidemiol. 2008;23(3):227-34. doi: 10.1007/s10654-007-9221-3. Epub 2008 Jan 16.


A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients.

Etard JF, Lanièce I, Fall MB, Cilote V, Blazejewski L, Diop K, Desclaux A, Ecochard R, Ndoye I, Delaporte E; ANRS 1215/1290 Study Group.

Trop Med Int Health. 2007 Oct;12(10):1191-8.


No evidence for recombination between HIV type 1 and HIV type 2 within the envelope region in dually seropositive individuals from Senegal.

Curlin ME, Gottlieb GS, Hawes SE, Sow PS, Ndoye I, Critchlow CW, Kiviat NB, Mullins JI.

AIDS Res Hum Retroviruses. 2004 Sep;20(9):958-63.


Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa.

Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Coll-Seck AM, Curlin ME, Critchlow CW, Kiviat NB, Mullins JI.

AIDS Res Hum Retroviruses. 2003 Jul;19(7):575-84.


Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, Faye-Niang MA, Diop A, Kuypers JM, Critchlow CW, Respess R, Mullins JI, Kiviat NB.

J Infect Dis. 2002 Apr 1;185(7):905-14. Epub 2002 Mar 19.


Supplemental Content

Loading ...
Support Center